Novai

Novai
Led by Biotech, Finance, and Pharmaceutical Veterans, Novai has been developing DARC (Detection of Apoptosing Retinal Cells) for over 10 years and has already received over £4m from the Wellcome Trust and UCL to take it to Phase 2 clinical trials (132 Patients to date). DARC combines a patented biomarker and state of the art AI algorithm which allows pharmaceutical companies to reduce the time, cost and risk of developing new drugs. Novai aims to reduce the clinical drug development period from years to months, as well as catch and monitor disease progression in trial patients.
Business Highlights
lock
Video
lock
Investment Deck
lock
Team
lock

03Other opportunities

Algbra (SFC Nominee)

Algbra (SFC Nominee)

Invest in the global Islamic fintech platform
Fund Size £2m EIS
SFC Angel Fund VIII SEIS

SFC Angel Fund VIII SEIS

Invest in a portfolio of innovative new businesses across the UK
Fund Size £20M SEIS
SFC Angel Fund VIII EIS

SFC Angel Fund VIII EIS

Invest in the Top 10% performers of SFC’s existing portfolio.
Fund Size £10M EIS
Medwise AI Ltd Medwise AI Ltd cover

Medwise AI Ltd

Instant answers to your clinical questions
Raising TBD SEIS/EIS